# Europass Curriculum Vitae

## Personal information


| | |
|---|---|
| First name(s) / Surname(s) | **Giuseppe Giannini** |
| Address(es) | Dept. of Molecular Medicine,<br>Faculty of Pharmacy and Medicine, University “La Sapienza”,<br>Viale Regina Elena 291, 00161 Rome, ITALY |
| Telephone(s) | +39 06 4958637, 06 49255662 |
| Fax(es) | +39 06 4461974, 06 49255660 |
| E-mail | giuseppe.giannini@uniroma1.it |
| Nationality | Italian |
| Gender | Male |


## Occupational field

General Pathology SSD MED/04

## Present Position

Full Professor, General Pathology, Dept. of Molecular Medicine, University “La Sapienza”
Since Dec. 31, 2011

Head, Molecular Oncology Unit, Policlinico Umberto I, Rome
Since 20168

## Work experience

Academic, Medical and Scientific Positions

| | |
|---|---|
| 2008 - 2016: | Head, Section of Molecular Diagnosis of Hereditary Tumors, Policlinico Umberto I, Rome |
| 2001 - 2011: | Associate Professor, SSD MED/04 General Pathology and |
| 1998 - 2001 | Assistant Professor, SSD MED/04 General Pathology. Dept. Experimental Medicine, Faculty of Medicine and Surgery, University “La Sapienza”, Rome |
| 1998 - 2008: | MD, Molecular Pathology and Gene Therapy Unit, Policlinico Umberto I, Rome |
| 1996 - 1997: | Visiting Scientist at the Cellular and Molecular Biology Section, National Cancer Institute, NIH, Bethesda, Maryland, USA |
| 1990 -1993: | Postdoctoral Research Associate in the Director’s Group, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany |
| 1989 - 1990: | Scientist, Raggio Italgene SPA, Pomezia (RM), Italy |

| | |
|---|---|
| Other Positions | Since 2016: Member Commissione Assistenza Interfacoltà, Università La Sapienza, Roma.<br>Since 2013: Member PhD School in "Tecnologie Biomediche in Medicina Clinica", University La Sapienza, Rome.<br>Since 2001: Member PhD School in "Medicina Molecolare" (ex "Endocrinologia e Medicina Molecolare"), University La Sapienza, Rome.<br>2006 - 2007: Member National Committee for evaluation of Italian University Researchers<br>2002 – 2004: Member Scientific Council of the Italian Neuroblastoma Foundation<br>2002 - 2003: Member National Committee for evaluation of Italian University Researchers<br>2000 – 2003: Member Commissione Risorse della Facoltà di Medicina e Chirurgia, University La Sapienza, Rome.<br>1998-2001: Member of the committee for the evaluation of the research projects for POP Calabria 1994/99 - Mis.4.4 "Ricerca Scientifica e Tecnologica" |

## Education and training

| | |
|---|---|
| Dates<br>Title of qualification awarded<br>Name and type of organisation providing education and training | 1997: Degree cum laude. Post-graduate Specialty School in Oncology, School of Medicine, University of L'Aquila, Italy<br>1990: Degree cum laude. Post-graduate Specialty School in Allergic Disease, School of Medicine, University La Sapienza, Rome, Italy<br>1987: Medical Doctor, Degree cum laude. School of Medicine, University La Sapienza, Rome, Italy |

AWARDS

1996: International Fogarty Center award (2 years fellowship).
1992: Istituto Pasteur - Fondazione Cenci-Bolognetti (2 years international fellowship)
1990: Associazione Italiana Ricerca contro il Cancro (AIRC, 2 years international fellowship)

## Personal skills and competences

MAIN RESEARCH FIELDS

- Molecular Biology Of Neuroectodermal Tumors
- Cellular Responses To DNA Damage
- Oncogenes And The DNA Damage Response
- Breast And Colorectal Cancer Genetics

FINANCED RESEARCH GRANTS

2016-2018: Insights into the functions of DNA damage processing and repair factors to design novel selective anticancer drugs. PRIN 2015, Responsabile di Unità.

2016-2019: The MRN complex and PARP: targeting the replication stress response in MYCN dependent neuronal tumors. Finanziamento AIRC Investigator Grant 2015

2015-2017: Functional interactions between the MRN complex and N-Myc in neuronal development and carcinogenesis. Responsabile del progetto. Finanziamento Programmi di Ricerca Istituto Pasteur – Fondazione Cenci Bolognetti.

2014: Uncovering the functional links between MYCN and the MRN complex to understand the phenotypic overlap between Nijmegen Breakage syndrome and Feingold syndrome. Ricerca Scientifica di Ateneo. Responsabile del progetto. Finanziamento Progetti "AWARDS".

2012: The DNA Damage Response (DDR) as a potential therapeutic target for MYCN-dependent tumors. Finanziamento di Ateneo anno 2012.

2011- 2014: Crosstalk between the DNA Damage Response pathway and MYCN in neuronal development and carcinogenesis. Finanziamento AIRC Investigator Grant 2011.

2010: "Understanding the molecular functions of Myc proteins at the border between proliferation and apoptosis: implications for new therapies". Finanziamento di Ateneo anno 2010.

2008-2010: "Caratterizzazione biomolecolare dei tumori ereditari della mammella e dell'ovaio finalizzata allo sviluppo di strategie diagnostico-terapeutiche personalizzate". Cofin 2008.

2004-2005: "Alterazioni dei meccanismi di riparo del DNA e dei sistemi recettoriali tirosina-chinasi come punto di partenza per la comprensione dei meccanismi molecolari di sviluppo e differenziamento e la designazione di nuovi approcci terapeutici per i tumori testicolari delle cellule germinali e di Leydig". Cofin 2004.

2003-2004: "Uso di tecnologie innovative per l'identificazione di bersagli molecolari nelle patologie neoplastiche sporadiche ed ereditarie. Responsabile di Unità operativa, Finanziamento Ministero della Salute

2003-2004: "Biological role of the HMGA proteins and molecular mechanisms of resistance to vitamin A in human neuroblastoma". Fondazione Italiana per la lotta al Neuroblastoma.

2002-2003: "Determinanti Molecolari di aggressività e terapie innovative nei tumori solidi pediatrici". Responsabile di Unità operativa, Finanziamento Ministero della Salute

2002-2003: "L'instabilità genetica nei tumori: studio dei meccanismi molecolari e applicazioni in oncologia preditiva e terapia". Responsabile di Unità operativa, Finanziamento Ministero della Salute

1999-2002: "Biological role and diagnostic potential of the expression of HMGI family members in Neuroblastoma". Associazione Italiana per la lotta al Neuroblastoma.

Mother tongue(s) **Italian**

Other language(s) **English**

| Self-assessment | Understanding | | | | Speaking | | | | Writing | |
|---|---|---|---|---|---|---|---|---|---|---|
| *European level (*)* | Listening | | Reading | | Spoken interaction | | Spoken production | | | |
| **Language** | | | | | | | | | | |
| **Language** | | | | | | | | | | |

*(*) Common European Framework of Reference for Languages*

## Additional information

Include here any other information that may be relevant, for example contact persons, references, etc.

Receiving

## Annexes

List any items attached.

## Scientific Publication

Bibliometry

| | | | |
|---|---|---|---|
| Peer reviewed publications: | 83; | last 5 yearsi: | 32 |
| Total Impact factor: | 664; | last 5 years: | 239 |
| Average Impact factor: | 8; | last 5 years: | 7,45 |
| H-Index: | 27 | | |
| Total citations: | 2610 | | |

Scopus Author ID: 7101749968;
WOS ID: B-5672-2013.
ORCID: http://orcid.org/0000-0003-0299-4056.

**SELECTION OF 30 PUBLICATIONS (LAST 15 YEARS)**

1. Colicchia V, Petroni M, Guarguaglini G, Ricci B, Sardina F, Sahun Roncero M, Heil C, Capalbo C, Belardinilli F, Coppa A, Screpanti I, Lavia P, Gulino A, Giannini G. The Poly (ADP-ribose) polymerase inhibitor olaparib enhances replication stress and causes mitotic catastrophe in MYCN amplified neuroblastoma. **Oncogene**, *in press* — 7.932

2. Veschi V, Liu Z, Voss TC, Ozbun L, Gryder B, Yan C, Hu Y, Ma A, Jin J, Mazur SJ, Lam N, Souza BK, Giannini G, Hager GL, Arrowsmith CH, Khan J, Appella E, Thiele CJ. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. **Cancer Cell.** 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002. — 23.214

3. Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. **Journal of Experimental & Clinical Cancer Research**. 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3. — 4.357

4. Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. ***Cell Death and Differentiation***. 2016 Feb;23(2):197-206. doi: 10.1038/cdd.2015.81. Epub 2015 Jun 12. — 8.218

5. Silvestri V, Rizzolo P, Scarnò M, Chillemi G, Navazio AS, Valentini V, Zelli V, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, Pensotti V, Peterlongo P, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Viel A, Montagna M, Radice P, Palli D, Ottini L. Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. ***European Journal of Cancer***. 2015 Nov;51(16):2289-95. doi: 10.1016/j.ejca.2015.07.020. — 6.163

6. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, ..... Giannini G, ..... Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. ***Journal of the American Medical Association***. 2015 Apr 7;313(13):1347-61. doi: 10.1001/jama.2014.5985 — 37.684

7. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, ..... Giannini G, ..... Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. ***Breast Cancer Research***. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9. — 5.211

8. Coppa A, Buffone A, Capalbo C, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani M, Ferraro S, Screpanti I, Gulino A, Giannini G. Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14. ***Breast Cancer Research and Treatment***. 2014 Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. — 4.085

9. Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A and Giannini G. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. ***Cell Death and Disease***. 2014, **5**, e1100; doi:10.1038/cddis.2014.68 Published online 6 March 2014 — 5.378

10. Mazzà D, Infante P, Colicchia V, Greco A, Alfonsi R, Siler M, Antonucci L, Po A, De Smaele E, Ferretti E, Capalbo C, Bellavia D, Canettieri G, Giannini G, Screpanti I, Gulino A, Di Marcotullio L. PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. ***Cell Death and Differentiation***. 2013 Dec;20(12):1688-97. doi: 10.1038/cdd.2013.120. — 8.218

11. Bojesen SE, Pooley KA, Johnatty SE,.....Giannini G., .....Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. ***Nature Genetics***. 2013 Apr;45(4):371-84. — 31.616

12. Orr N, Lemnrau A, Cooke R, Fletcher O, Tomczyk K, Jones M, Johnson N, Lord CJ, Mitsopoulos C, Zvelebil M, McDade SS, Buck G, Blancher C; KConFab Consortium, Trainer AH, James PA, Bojesen SE, Bokmand S, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, Giannini G, Hollestelle A, Ouweland AM, Novaković S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Easton DF, Pharoah PD, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Houlston RS, Garcia-Closas M, Ashworth A, Swerdlow AJ. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. ***Nature Genetics***. 2012 Sep 23;44(11):1182-4. doi: 10.1038/ng.2417. 31.616

13. Antoniou AC, Kartsonaki C, …….. Giannini G, ……. Easton DF, Chenevix-Trench G; on behalf of CIMBA. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carrier. ***Human Molecular Genetics***. 2011 Aug 15;20(16):3304-3321. 5.985

14. Petroni M, Veschi V, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, Dominici C, McDowell HP, Rinaldi C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Soddu S, Giannini G. MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. ***Molecular Cancer Research***. 2011 Jan;9(1):67-77. 4.510

15. Forloni M, Albini S, Limongi MZ, Cifaldi L, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D. NF-{kappa}B, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells. **Cancer Research**. 2010 Feb 1;70(3):916-24. 8.556

16. Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, Galardi S, Buè MC, Massalini S, McDowell HP, Messi E, Gulino A, Farace MG, Ciafrè SA. MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. ***FASEB Journal.*** 2009 Dec;23(12):4276-87. 5.299

17. Canettieri G, Coni S, Della Guardia M, Nocerino V, Antonucci L, Di Magno L, Screaton R, Screpanti I, Giannini G, Gulino A. The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. ***Proc Natl Acad Sci U S A.*** 2009 Feb 3;106(5):1445-50. 9.423

18. Giannini G, Capalbo C, Ottini L, Buffone A, De Marchis L, Margaria E, Vitolo D, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Marchetti P, Cortesi E, Frati L, Screpanti I, and Gulino A. On the clinical classification of BRCA1 DNA missense variants: the H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant "THV" motif of the N-terminal BRCT domain. ***Journal of Clinical Oncology.*** 2008 Sep 1;26(25):4212-4214. 20.982

19. Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A and Giannini G. Does search for large genomic rearrangements impact on BRCAPRO carrier prediction? ***Journal of Clinical Oncology***, 2007 Jun 20;25(18):2632-4 20.982

20. Buffone A, Capalbo C, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. ***Breast Cancer Research and Treatment.*** 2007. Dec;106(2):289-96. 4.085

21. Di Marcotullio L, Ferretti E, Greco A, De Smaele E, Po A, Sico MA, Alimandi M, Giannini G, Maroder M, Screpanti I, Gulino A. Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. ***Nature Cell Biology.*** 2006 Dec;8(12):1415-23. 18.699

22. Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone A, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. ***Annals of Oncology***. 2006 Jun;17 Suppl 7:vii34-vii40. 9.269

23. Giannini G, Capalbo C, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. ***Breast Cancer Research and Treatment.*** 2006 Nov;100(1):83-91. 4.085

24. Palma M, Ristori E, Ricevuto E, Giannini G and Gulino A. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. ***Critical Reviews in Oncology/Hematology***. 2006 Jan;57(1):1-23. 5.039

25. Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Dominici C, Frati L, Screpanti I, Gulino A. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. ***Cancer Research.*** 2005 Sep 15;65(18):8308-16. 8.556

26. Giannini G, Cerignoli F, Mellone M, Massimi I, Ambrosi C, Rinaldi C, Gulino A. Molecular mechanism of HMGA1 deregulation in human Neuroblastoma. ***Cancer Letters.*** 2005 Oct 18;228(1-2):97-104. 5.992

27. Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, Bidoli E, Berni S, D'Amati G, Scambia G, Frati L, Screpanti I. and Gulino A. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. ***Oncogene***, 2004 Apr; 23(15): 2640-2647. 7.932

28. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, Ottini L, Crescenzi M, Martinotti S, Bignami M, Frati L and Gulino A. Human MRE11 is inactivated in mismatch repair deficient cancers. ***EMBO Reports***, 2002, 3(3), 248-254***.*** 7.739

29. Cerignoli F, Guo X, Cardinali B, Rinaldi C, Casaletto J, Frati L, Screpanti I, Gudas LJ, Gulino A, Thiele CJ and Giannini G. RetSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid inducible and frequently deleted in neuroblastoma cell lines. ***Cancer Research****,* 2002, 62, 1196-1204. 8.556

30. Capalbo C, Ricevuto E, Vestri A, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A and Giannini G. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customised IC software. ***European Journal of Human Genetics.*** 2006 Jan;14(1):49-54. 4.580

FIRMATO: GIUSEPPE GIANNINI